Get the Stockscreener App
3.42
2.10%
0.09
Kyverna Therapeutics Inc stock is traded at $3.42, with a volume of 77,556.
It is up +2.10% in the last 24 hours and up +33.33% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$3.33
Open:
$3.34
24h Volume:
77,556
Relative Volume:
0.18
Market Cap:
$147.38M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-1.1045
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
-4.76%
1M Performance:
+33.33%
6M Performance:
+13.33%
1Y Performance:
-51.29%
1-Day Range:
$3.325
$3.42
1-Week Range:
$3.25
$3.56
52-Week Range:
$1.78
$8.78
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
3.41 | 147.38M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.39 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.23 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.14 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.82 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $15.60 Average Target Price from Analysts - MarketBeat
Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Monday - MarketBeat
What are analysts’ price targets for Kyverna Therapeutics Inc. in the next 12 monthsInvest confidently with data-driven strategies - Jammu Links News
What is the risk reward ratio of investing in Kyverna Therapeutics Inc. stockInvest confidently with expert support - Jammu Links News
How does Kyverna Therapeutics Inc. generate profit in a changing economyUnlock real-time stock alerts for quick profits - Jammu Links News
What are the latest earnings results for Kyverna Therapeutics Inc.Expert guidance for superior capital growth - Jammu Links News
What analysts say about Kyverna Therapeutics Inc. stockCapital growth strategies that work - Jammu Links News
Is Kyverna Therapeutics Inc. a growth stock or a value stockAchieve superior capital gains with smart trades - Jammu Links News
What institutional investors are buying Kyverna Therapeutics Inc. stockGet expert advice on portfolio optimization - Jammu Links News
What are Kyverna Therapeutics Inc. company’s key revenue driversOutstanding growth strategies - Jammu Links News
Does Kyverna Therapeutics Inc. stock perform well during market downturnsBuild wealth faster with consistent growth stocks - Jammu Links News
What are the technical indicators suggesting about Kyverna Therapeutics Inc.Build a portfolio for long-term financial success - Jammu Links News
Is it the right time to buy Kyverna Therapeutics Inc. stockCapitalize on fast-growing investment opportunities - Jammu Links News
How volatile is Kyverna Therapeutics Inc. stock compared to the marketDynamic profit expansion - Jammu Links News
What catalysts could drive Kyverna Therapeutics Inc. stock higher in 2025High-profit capital plays - Jammu Links News
Should I hold or sell Kyverna Therapeutics Inc. stock in 2025Maximize gains with professional stock picks - jammulinksnews.com
How strong is Kyverna Therapeutics Inc. company’s balance sheetStock Strategy Recommendation From AI Tools - Jammu Links News
Is Kyverna Therapeutics Inc. stock overvalued or undervaluedPost Market Guidance For Smart Trading - jammulinksnews.com
Exit strategy if you’re trapped in Kyverna Therapeutics Inc.Short Term Setup With Predictive Chart Confirmed - metal.it
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionKYTX - ACCESS Newswire
Analysts Apply Wyckoff Model to Kyverna Therapeutics Inc. StockPattern Detection for Entry Confirmation Enabled - beatles.ru
Trendlines Suggest Kyverna Therapeutics Inc. May Bottom Out SoonWeekly Return Pick Forecast Reports Show Trend - metal.it
Rising Star: Covington's Alicia Zhang - Law360
Kyverna Appoints New CFO to Guide Next Growth Phase - Insider Monkey
Kyverna Therapeutics to Host Virtual KOL Event on Neuroimmunology CAR T Franchise - AInvest
Leading Neurologists Reveal Game-Changing CAR T Treatment for Rare Autoimmune Disorders - Stock Titan
Published on: 2025-07-29 14:03:16 - metal.it
What does KYTX's flat EPS in 2024 indicate for investors? - AInvest
11 Best New Penny Stocks to Buy Right Now - Insider Monkey
What institutions are buying Kyverna Therapeutics Inc. stock nowDaily Smart Money Movement Monitor Activated - metal.it
Why did Kyverna's operating expenses surge in Q4 2024? - AInvest
How many analysts rate Kyverna Therapeutics Inc. as a “Buy”Breakout Stocks Strategy With Low Risk - jammulinksnews.com
Why is Kyverna Therapeutics Inc. stock attracting strong analyst attentionBest Dividend Tips From AI Tools - Jammu Links News
Published on: 2025-07-28 19:09:23 - metal.it
What is the dividend policy of Kyverna Therapeutics Inc. stockAchieve breakthrough gains with smart trades - Jammu Links News
Will Kyverna Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsHigh Return Investment Tips - Newser
Published on: 2025-07-27 18:04:27 - Jammu Links News
How Kyverna Therapeutics Inc. stock performs during market volatilityFree Access to Investment Community - Newser
Why Kyverna Therapeutics Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):